IN8BIO, Inc.
INAB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001740279
No open-market purchases or sales by IN8BIO, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $5.35M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding IN8BIO, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 13 | 14 | +1 |
| Shares | 1.77M | 1.78M | +4.62K (+0.3%) |
| Value | $12.2M | $7.80M | −$4.39M (−36.0%) |
New holders (4)
Institutions that held IN8BIO, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ensign Peak Advisors, Inc | 70,028 | $307.0K | 0.00% |
| Sigma Planning Corp | 28,600 | $126.0K | 0.00% |
| HighTower Advisors, LLC | 10,000 | $44.0K | 0.00% |
| Bank of America Corp | 7 | $0 | 0.00% |
Sold out (3)
Institutions that held IN8BIO, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Tudor Investment Corp Et Al | 63,287 | $434.0K |
| Rock Creek Group, LP | 42,279 | $292.0K |
| Millennium Management LLC | 25,340 | $175.0K |